TABLE 2.
Mortality outcomes in COVID‐19 patients treated with plasma exchange
| Author | Published | Design | Population | n | Treatment | Outcomes |
|---|---|---|---|---|---|---|
| Adeli et al. | May 2020 | Single‐center, case series | Respiratory distress or mechanical ventilation | 8 | Three to five sessions, 2000 ml plasma volume, 500 ml 5% Human albumin, 4 units FFP, and 0.9% saline | In‐hospital mortality 12.5% |
| Keith et al. | September 2020 | Single‐center, case series | Sepsis, acute respiratory distress, and multi‐organ failure | 8 | Two to seven sessions, 1.0 plasma volume, FFP | In‐hospital‐mortality 25% |
| Hashemian et al. | December 2020 | Single‐center, case series | Acute respiratory distress | 15 | NA (every second day), 40 ml/kg plasma volume, 5% Human albumin and 0.9% saline or FFP | In‐hospital mortality 40% |
| Dogan et al. | May 2020 | Single center, case series | COVID‐19 related autoimmune meningoencephalitis | 6 | Six to nine sessions, NA, 5% Human albumin | In‐hospital mortality 16.7% |
| Gucyetmez et al. | August 2020 | Multi‐center, case series | Critical illness, ICU admission | 18 | Three sessions, NA, NA | In‐hospital mortality 16.7% |
| Faqihi et al. | December 2020 | Single‐center, pilot study | Mechanical ventilation and multi‐organ failure | 10 | Five to seven sessions, 1.0–1.5 plasma volumes, 5% Human albumin or FFP | 28‐day mortality 10% |
| de Prost et al. | January 2021 | Single‐center, case series | Critical illness and neutralizing antibodies against type I interferons | 4 | Three to four sessions, NA, NA | In‐hospital mortality 50% |
| Khamis et al. | June 2020 | Single‐center, case series | Acute respiratory distress and multi‐organ failure | 11 | Five sessions, hematocrit‐adjusted plasma volume, FFP | Mortality 9.1% |
| Morath et al. | August 2020 | Single center, case series | Respiratory failure | 5 | One to two sessions, median 3.4 L plasma volume, FFP | Mortality 40% |
| Matsushita et al. | December 2020 | Single‐center, case series | Respiratory distress or mechanical ventilation | 5 | Three to seven sessions, 2500–3000 ml plasma volumes, FFP | 30‐day mortality 40% |
| Faqihi et al. | April 2021 | Single‐center open‐label, randomized clinical trial | Mechanical ventilation and multi‐organ failure | PLEX: 43 Controls: 44 | One to five sessions, 1.0–1.5 plasma volumes, FFP or Octaplas LG | 35‐day mortality: PLEX 20.9% Controls 11.4%, p = 0.572 |
| Truong et al. | December 2020 | Single‐center, case series | Critical illness and hyperviscosity | 6 | Two to three sessions, NA, NA | In‐hospital mortality 33% |
| Jaiswal et al. | January 2021 | Multi‐center, case series | Respiratory failure with acute respiratory distress or shock | 14 | One session, 30–40 ml/kg plasma volume, convalescent plasma | 28‐day mortality 28.6% |
| Kamran et al. | January 2021 | Retrospective propensity‐score matched cohort | Cytokine release syndrome (male only) | PLEX: 45 Controls: 45 | NA (once daily), 1.5 plasma volumes, FFP and 0.9% saline 2:1 | All‐cause mortality: PLEX 9.9% Matched controls 38.5%, p < 0.001 |
| 198 | Mortality: 20.2% |
Abbreviations: FFP, Fresh frozen plasma; ICU, Intensive care unit; NA, Not available; PLEX, Plasma exchange.